Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.

Autor: Soffer D; Perelman School of Medicine, University of Pennsylvania, 34th and Civic Center Blvd., Philadelphia, PA 19104, USA., Stoekenbroek R; US Clinical Development and Medical Affairs, Novartis Pharmaceuticals Corporation, One Health Plaza, Building 125, East Hanover, NJ 07936, USA. Electronic address: rstoeken@gmail.com., Plakogiannis R; Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, 75 Dekalb Avenue, Brooklyn, NY 11201, USA.
Jazyk: angličtina
Zdroj: Journal of clinical lipidology [J Clin Lipidol] 2022 Sep-Oct; Vol. 16 (5), pp. 574-582. Date of Electronic Publication: 2022 Jun 28.
DOI: 10.1016/j.jacl.2022.06.009
Abstrakt: Despite the development of new therapies to lower cardiovascular disease (CVD) risk in recent decades, the trend of reductions in CVD mortality has reversed. New therapies are essential for the prevention of first and recurrent CVD. The importance of lowering low-density lipoprotein cholesterol (LDL-C) in the management and prevention of atherosclerotic CVD (ASCVD) is widely reflected in clinical treatment guidelines; however, most patients with established ASCVD do not achieve guideline-recommended LDL-C targets. Common reasons include adherence challenges, public disinformation, statin tolerability issues, access barriers, and clinical inertia. Inclisiran is a novel small interfering ribonucleic acid (RNA) that lowers circulating LDL-C by ∼50% when added to maximally tolerated statins by mimicking the body's natural pathway of RNA interference to specifically prevent proprotein convertase subtilisin/kexin type 9 synthesis. The unique dosing regimen of inclisiran (initial, at 3 months, and then every 6 months) has the advantage of allowing for healthcare provider administration during recommended routine visits for patients with established ASCVD, which can circumvent adherence issues associated with currently available LDL-C-lowering therapies. Inclisiran has demonstrated favorable tolerability and safety for up to 3 years, and evidence from longer-term use is accumulating in ongoing studies. This review discusses the novel mechanism of action of inclisiran and its potential position in the clinical armamentarium.
Competing Interests: Declaration of Competing Interest R.S. is an employee of Novartis Pharmaceuticals Corporation. D.S. is a consultant for Akcea Therapeutics and Novartis Pharmaceuticals Corporation, and a clinical trial investigator for Ionis, Amgen, AstraZeneca, Novartis, Regeneron, and REGENXBIO. R.P. has nothing to disclose.
(Copyright © 2022. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: